Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - Fibrocell Science, Inc. | a14-20392_1ex10d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2014
FIBROCELL SCIENCE, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-31564 |
|
87-0458888 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of Incorporation) |
|
File Number) |
|
Identification No.) |
405 EAGLEVIEW BLVD., EXTON, PA 19341
(Address of Principal Executive Office) (Zip Code)
(484) 713-6000
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 28, 2014, the Compensation Committee of the Board of Directors of Fibrocell Science, Inc. (the “Company”) approved a salary increase for Gregory Weaver, the Company’s Senior Vice President and Chief Financial Officer, from $300,000 to $330,000. This salary increase was documented in an amendment dated September 2, 2014 (the “Amendment”) to Mr. Weaver’s employment agreement originally dated August 26, 2013.
A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description |
|
|
|
|
|
10.1 |
|
Amendment to Employment Agreement, dated September 2, 2014, by and between the Company and Gregory Weaver. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
FIBROCELL SCIENCE, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Gregory Weaver |
|
|
|
Gregory Weaver |
|
|
|
Chief Financial Officer |
|
Date: September 3, 2014 |
|
|